



Management of Vulvar Cancer

Guest Editors:

Dr. Giacomo Corrado

Department of Woman's and
Child Health and Public Health
Sciences, Gynecologic Oncology
Unit, Fondazione Policlinico
Universitario Agostino Gemelli
IRCCS, 00168 Rome, Italy

Prof. Giorgia Garganese

1. Gynecology and Breast Care
Center, Mater Olbia Hospital,
Strada Statale 125 Orientale
Sarda, 07026 Olbia, Italy
2. Department of Life Sciences
and Public Health, Catholic
University of the Sacred Heart,
L.go A. Gemelli 8, 00168 Rome,
Italy

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors

Dear Colleagues,

Vulvar cancer (VC) is a rare malignancy, accounting for an estimated 5.6% of all gynecologic malignancies and 3.7% of gynecologic cancer deaths. Ninety percent of primary VCs are squamous cell carcinoma (SCC), while other rare histologies include Bartholin gland adenocarcinoma, melanoma, extra-mammary Paget's disease, verrucous carcinoma, basal cell carcinoma, and sarcoma. Risk factors for the development of vulvar neoplasia include old age, human papillomavirus infection, cigarette smoking, inflammatory conditions, and immunodeficiency. A surgical and reconstructive treatment approach has so far been a cornerstone of the different strategies at both initial and advanced stages. Significant advances have been made over time in pre-operative work-up and surgical planning, turning from 'en-bloc' surgery, which is burdened by the highest morbidity, to more conservative approaches without compromising oncologic safety. Moreover, the integration with other treatments, such as radio-chemotherapy, brachytherapy, or electrochemotherapy, has improved overall clinical outcomes, allowing for additional opportunity even in cases unsuitable for upfront surgery.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI